Skip to main content
ZYME
NASDAQ Life Sciences

FDA Grants Fast Track to Zymeworks' ZW191 for Ovarian Cancer, Accelerating Development

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$24.9
Mkt Cap
$1.797B
52W Low
$9.03
52W High
$28.49
52W Position info
176% above low
Off High info
13% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ZYME has more than doubled off its 52-week low of $9.03.

Summary

Zymeworks Inc. has received U.S. FDA Fast Track designation for its investigational antibody-drug conjugate (ADC), ZW191, targeting folate receptor-α (FRα) for advanced or metastatic platinum-resistant ovarian cancer. This designation is a significant positive development as it aims to expedite the drug's development and review process, potentially accelerating its path to market and addressing a high unmet medical need. The news reinforces the potential of Zymeworks' ADC platform and follows the company's recent financial strengthening with a $250 million loan. Investors will now closely monitor the ongoing Phase 1 clinical study for ZW191 and subsequent clinical trial milestones.

At the time of this announcement, ZYME was trading at $24.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.03 to $28.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ZYME - Latest Insights

ZYME
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $31.00 info
Change: +$0.190 (+0.62%) info
Market Cap: $2.188B info
ZYME
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $31.00 info
Change: +$0.190 (+0.62%) info
Market Cap: $2.188B info
ZYME
Nov 09, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.81
Real-time Price: $31.00 info
Change: +$0.190 (+0.62%) info
Market Cap: $2.188B info
ZYME
Oct 24, 2026, 2:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.55
Real-time Price: $31.00 info
Change: +$2.45 (+9%) info
Market Cap: $2.188B info
ZYME
Oct 23, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.99
Real-time Price: $31.00 info
Change: +$2.01 (+7%) info
Market Cap: $2.188B info